Page 4 - பிரிட்டன் தேசிய ஆரோக்கியம் சேவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Message : Required fields (Reuters) -Britain s competition watchdog is sticking with its view that Pfizer and Flynn Pharma broke the law by charging Britain s public health service unfairly high prices for an epilepsy drug, after being asked to reassess a record fine. The drugmakers made use of a loophole so that the capsules, branded Epanutin prior to September 2012, were not subject to price regulation for branded drugs, the Competition and Markets Authority (CMA) found in its provisional review https://www.gov.uk/government/news/cma-accuses-pharma-firms-of-illegal-pricing. In 2016, the CMA fined https://www.reuters.com/article/us-pfizer-britain-fine-idUSKBN13W0VT Pfizer and Flynn a record 90 million pounds ($125 million) for the price hike. However, the companies in 2018 won an appeal https://www.reuters.com/article/uk-pfizer-britain-fine-idUKKCN1J327D against the penalty, and the Competition Appeal Tribunal referred the matter back to the CMA.

United kingdomMark potterPushkala aripakaBritain national health serviceMarkets authorityCompetition appeal tribunalNational health serviceBengaluru editingRashmi aichஒன்றுபட்டது கிஂக்டம்குறி பாடர்பிரிட்டன் தேசிய ஆரோக்கியம் சேவைசந்தைகள் அதிகாரம்போட்டி முறையீடு தீர்ப்பாயம்தேசிய ஆரோக்கியம் சேவைபெங்களூரு திருத்துதல்